Matthew J. Frigault

机构：Harvard University, Massachusetts General Hospital, Center for Cancer Research, Mass General Brigham · ORCID：0000-0002-6774-5694

发表论文 317 篇 · 总被引 12575 次 · h-index 47

代表论文

• Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1 (2025 · Blood · 被引 12)
• Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea (2026 · Blood · 被引 7)
• Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy (2026 · Transplantation and Cellular Therapy · 被引 3)
• Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma (2026 · Blood · 被引 3)
• Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma (2026 · Journal of Hematology & Oncology · 被引 3)
• First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance (2025 · Blood · 被引 3)